Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models

Although androgen ablation therapy is the foundation of current prostate cancer treatment, most patients ultimately develop castration-resistant disease. One proposed mechanism to account for androgen receptor (AR) activity in the castrate environment is via crosstalk with other signaling pathways....

Descripción completa

Detalles Bibliográficos
Autores principales: SQUILLACE, RACHEL M., MILLER, DAVID, WARDWELL, SCOTT D., WANG, FRANK, CLACKSON, TIM, RIVERA, VICTOR M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2012
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582879/
https://www.ncbi.nlm.nih.gov/pubmed/22614157
http://dx.doi.org/10.3892/ijo.2012.1487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582879/
https://www.ncbi.nlm.nih.gov/pubmed/22614157
http://dx.doi.org/10.3892/ijo.2012.1487

Ejemplares similares